u/mass_spec_maggie

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

boring is the objective now

The system suitability argument, since it comes up whenever somebody posts a number without one.

Before the sample result means anything, the instrument has to be shown to be fit that day: replicate injections with an acceptable RSD on area, a tailing factor inside limits, adequate plate count, and a resolution check between the pair you care about.

None of that is exotic and all of it is routine in a laboratory that reports for a living. Its absence does not mean a number is wrong; it means the number is unanchored, and unanchored numbers should not be quoted to two decimal places on this board.

regain after stopping is the expected outcome, not a personal failure

baseline choice is a decision, not a measurement

That is a range, not a trend. Two weigh-ins 11 days apart cannot distinguish them.

Why contemporaneous beats reconstructed, with the failure mode.

Memory smooths. Reconstructing a fortnight from recollection produces a series that is more regular, more consistent with your current beliefs, and quietly wrong in a direction that flatters the story you are already telling.

I found this out by reconstructing six weeks and later finding order receipts that contradicted my own entries. The log was not a little wrong; it was wrong in exactly the direction that made my narrative work. Write it down on the day, even the boring days, especially the boring days.

Do you have the mass, or only the UV trace?

Agreed, and it is why GL Biochem printing the column and gradient on the certificate is genuinely useful rather than decorative.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

Stretched from seven to ten days and then to twelve over about four months. Appetite told me where the limit was before the scale did.

Small fix — that is a reconstructed entry rather than a contemporaneous one, and the post presents it as the latter.

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

you cannot report to two decimals off that baseline

The effect on gastric emptying is most pronounced early and attenuates with continued dosing, which is the mechanism behind the "it settles at a stable dose" pattern the whole board reports.

Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.

a log with no dates is a story

Agreed. Two analysts, one trace, two integration choices, and a spread that has nothing to do with the vial.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

sulphur burps for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

Keeping a log, and what to put in it.

One line a day: dose, day since injection, what the symptom was and how bad out of five, and roughly what you ate. Two months of that fits on one page and the pattern is obvious on paper in a way it never is in your head.

Mine showed a clean day-two-to-day-four window I had been describing as "random". Once you can see the pattern you can plan around it, and planning around it is most of the relief.

boring is the objective now

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

maintenance is a phase, not a finish line

Yes. Holding the dose is a real option and it does not mean you have failed at anything.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

Resolution between two peaks depends on retention, selectivity and efficiency. A shallower gradient buys retention and usually resolution, at the cost of peak width and run time.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

How long has it been going on for now?

Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.

What wavelength, and what was the gradient?

Sent the same vial to Janoshik and Medutest. 99.1% against a claimed 98.5%. The difference was the gradient, not the material.

Sent the same vial to PeptideMeter and VendorInvestigate.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

Interval stretching changes the exposure profile: with a week-long half-life, moving to ten or twelve days lowers trough concentration more than it lowers average exposure. That is why appetite return is often the first thing noticed.

A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

Not convinced by that integration. Dropping the baseline there absorbs part of the shoulder into the main peak.